General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Negotiations were not pursued
Manufacturer:
Sun Pharma Canada Inc.
Indication:
Basal Cell Carcinoma (BCC), locally advanced in adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery
Last updated June 4, 2021
Status:
Negotiations were not pursued
Manufacturer:
Celgene Inc.
Indication:
Multiple Myeloma (Relapsed)
Last updated June 4, 2021
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis In Patients with CFTR Gating Mutations or the R117H Gating Mutation
Last updated June 3, 2021
Orkambi (lumacaftor/ivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis, F508del CFTR mutation
Last updated June 3, 2021
Status:
Concluded with an LOI
Manufacturer:
Juno Pharmaceuticals Corp.
Indication:
Deep vein thrombosis (treatment and prevention)
Last updated May 27, 2021
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)
Last updated May 21, 2021
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Rheumatoid Arthritis
Last updated May 10, 2021
Status:
Concluded without agreement
Manufacturer:
UCB Canada Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated May 7, 2021
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Hodgkin's Lymphoma
Last updated April 28, 2021
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides)
Last updated April 28, 2021